SCHEMBL260754

SCHEMBL260754

C/C(=C1\C(=O)Nc2ccc(CN3C(=O)CSC3=O)cc21)c1cc(CN2CCOCC2)c[nH]1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.67
FGFR1 P11362 1/20 0.67
FGFR2 P21802 1/20 0.67
FGFR3 P22607 1/20 0.67
AXL P30530 1/20 0.67
AKT2 P31751 10/20 0.42
PDPK1 O15530 5/20 0.40
PDK1 Q15118 1/20 0.38
PDGFRB P09619 1/20 0.36
KDR P35968 1/20 0.36
POLB P06746 1/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL260755 1.00 MET (0.67) METFGFR1FGFR2FGFR3AXL
Hydrochloric Acid SCHEMBL260532 0.99 MET (0.66) METFGFR1FGFR2FGFR3AXL
Hydrochloric Acid SCHEMBL260531 0.99 MET (0.66) METFGFR1FGFR2FGFR3AXL
SCHEMBL261325 0.90 MET (0.65) METFGFR1FGFR2FGFR3AXL
SCHEMBL261324 0.90 MET (0.65) METFGFR1FGFR2FGFR3AXL
Hydrochloric Acid SCHEMBL261477 0.90 MET (0.64) METFGFR1FGFR2FGFR3AXL
Hydrochloric Acid SCHEMBL261478 0.90 MET (0.64) METFGFR1FGFR2FGFR3AXL
SCHEMBL1224740 0.86 MET (0.49) METFGFR1FGFR2FGFR3AXL
SCHEMBL1224741 0.86 MET (0.49) METFGFR1FGFR2FGFR3AXL
Hydrochloric Acid SCHEMBL260014 0.85 MET (0.48) METFGFR1FGFR2FGFR3AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653073-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2014-02-18 US disclosed
US-20130331380-A1 DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2013-12-12 US disclosed
US-8541412-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2013-09-24 US disclosed
EP-2281822-B1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them SERVIER LAB (FR) 2013-01-16 EP disclosed
US-8133889-B2 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-03-13 US disclosed
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-02-23 US disclosed
WO-2011015728-A1 NOVEL DIHYDROINDOLONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2011-02-10 WO disclosed
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-02-10 US disclosed
EP-2281822-A1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2011-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331380-A1 DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CYP11B1, SDHA, CYP11B2 MET 2084/4885FGFR1 875/4885FGFR2 2322/4885
US-20120046287-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 MET 2084/4885FGFR1 875/4885FGFR2 2322/4885
US-20110034460-A1 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them CYP11B1, SDHA, CYP11B2 MET 2084/4885FGFR1 875/4885FGFR2 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.